Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
暂无分享,去创建一个
P. Tonge | Hao Lu | Hao Lu | Peter J. Tonge
[1] P. Tonge,et al. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs. , 2003, Biochemistry.
[2] D. Livermore. The need for new antibiotics. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] Charles O. Rock,et al. erratum: A triclosan-resistant bacterial enzyme , 2000, Nature.
[4] David Alland,et al. Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase , 2003, Journal of Biological Chemistry.
[5] R. Bax,et al. The future challenges facing the development of new antimicrobial drugs , 2002, Nature Reviews Drug Discovery.
[6] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[7] P J Artymiuk,et al. Common themes in redox chemistry emerge from the X-ray structure of oilseed rape (Brassica napus) enoyl acyl carrier protein reductase. , 1995, Structure.
[8] W. Jacobs,et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.
[9] R. Slayden,et al. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis , 2000, Molecular microbiology.
[10] Xiayang Qiu,et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). , 2002, Journal of medicinal chemistry.
[11] Robert Stroud,et al. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.
[12] H. Bergler,et al. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. , 1996, European journal of biochemistry.
[13] Jie J. Zheng,et al. The structural biology of type II fatty acid biosynthesis. , 2005, Annual review of biochemistry.
[14] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[15] Antoni R. Slabas,et al. A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase , 1996, Science.
[16] P. Schultz,et al. Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis , 1995 .
[17] M. Mann,et al. Robust Salmonella metabolism limits possibilities for new antimicrobials , 2006, Nature.
[18] W. Jacobs,et al. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. , 1998, The Journal of infectious diseases.
[19] Kun Song,et al. Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase. , 2006, Journal of medicinal chemistry.
[20] M. Espinal,et al. Tuberculosis as a major global health problem in the 21st century: a WHO perspective. , 2004, Seminars in respiratory and critical care medicine.
[21] M. Head,et al. Defining and Combating the Mechanisms of Triclosan Resistance in Clinical Isolates of Staphylococcus aureus , 2002, Antimicrobial Agents and Chemotherapy.
[22] Jun Wang,et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.
[23] D. Williams. The glycopeptide story--how to kill the deadly 'superbugs'. , 1996, Natural product reports.
[24] L. A. Basso,et al. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. , 2004, Chemical communications.
[25] Deniz Tasdemir,et al. Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. , 2006, Journal of medicinal chemistry.
[26] T. Scior,et al. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review. , 2006, Current medicinal chemistry.
[27] J. Puglisi,et al. Structure of the A Site of Escherichia coli 16S Ribosomal RNA Complexed with an Aminoglycoside Antibiotic , 1996, Science.
[28] A. Maxwell. DNA gyrase as a drug target. , 1997, Trends in microbiology.
[29] Peter J. Tonge,et al. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Sharma,et al. Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). , 2007, Journal of medicinal chemistry.
[31] Xiayang Qiu,et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. , 2003, Journal of medicinal chemistry.
[32] S. Parikh,et al. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. , 2000, Biochemistry.
[33] K. Kumura,et al. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. , 2007, Bioorganic & medicinal chemistry.
[34] Tae-Gyu Lee,et al. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids , 2005, FEBS letters.
[35] R. Perozzo,et al. Anti-protozoal and plasmodial FabI enzyme inhibiting metabolites of Scrophularia lepidota roots. , 2005, Phytochemistry.
[36] Joel S. Freundlich,et al. X-ray Structural Analysis of Plasmodium falciparum Enoyl Acyl Carrier Protein Reductase as a Pathway toward the Optimization of Triclosan Antimalarial Efficacy* , 2007, Journal of Biological Chemistry.
[37] T. Schaeverbeke,et al. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas. , 1999, The Journal of antimicrobial chemotherapy.
[38] C. Vilchèze,et al. Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD+ and a C16 Fatty Acyl Substrate* , 1999, The Journal of Biological Chemistry.
[39] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[40] J. Hildebrandt,et al. Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues. , 1984, Journal of medicinal chemistry.
[41] P. Tonge,et al. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. , 2004, Journal of medicinal chemistry.
[42] Matthew W Vetting,et al. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid , 2006, Nature Structural &Molecular Biology.
[43] L. L. Ling,et al. Identification and Characterization of Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductase , 2022 .
[44] H. Schweizer,et al. High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. , 2003, American journal of infection control.
[45] R. Bax,et al. Antibiotic resistance - what can we do? , 1998, Nature Medicine.
[46] P. McDermott,et al. Genetic Evidence that InhA of Mycobacterium smegmatis Is a Target for Triclosan , 1999, Antimicrobial Agents and Chemotherapy.
[47] V. Bernardes-Génisson,et al. The first chemical synthesis of the core structure of the benzoylhydrazine-NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase. , 2005, The Journal of organic chemistry.
[48] M. Rosenberg,et al. Exploiting genomics to discover new antibiotics. , 2001, Trends in microbiology.
[49] D W Rice,et al. Mechanism of action of diazaborines. , 1998, Biochemical pharmacology.
[50] P. Warren,et al. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. , 2001, Drug discovery today.
[51] P. Tonge,et al. Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis. , 2007, Bioorganic & medicinal chemistry letters.
[52] S. Levy,et al. Triclosan targets lipid synthesis , 1998, Nature.
[53] J C Sacchettini,et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.
[54] J. W. Campbell,et al. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. , 2001, Annual review of microbiology.
[55] C. Rock,et al. Evaluation of Epigallocatechin Gallate and Related Plant Polyphenols as Inhibitors of the FabG and FabI Reductases of Bacterial Type II Fatty-acid Synthase* , 2004, Journal of Biological Chemistry.
[56] Christopher J. L. Murray,et al. Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.
[57] T. Ramya,et al. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. , 2006, Bioorganic & medicinal chemistry.
[58] A. Rattan,et al. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. , 1998, Emerging infectious diseases.
[59] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[60] Teresa Quitugua,et al. Single Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[61] C. Walsh. Molecular mechanisms that confer antibacterial drug resistance , 2000, Nature.
[62] R. Heath,et al. The Enoyl-[acyl-carrier-protein] Reductases FabI and FabL fromBacillus subtilis * , 2000, The Journal of Biological Chemistry.
[63] S. Parikh,et al. Structural basis and mechanism of enoyl reductase inhibition by triclosan. , 1999, Journal of molecular biology.
[64] A. Kochi,et al. The global tuberculosis situation and the new control strategy of the World Health Organization. , 1991, Tubercle.
[65] S. Chirala,et al. Animal fatty acid synthase: functional mapping and cloning and expression of the domain I constituent activities. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Dubos,et al. THE ISOLATION OF BACTERICIDAL SUBSTANCES FROM CULTURES OF BACILLUS BREVIS , 1941 .
[67] M. Blacow,et al. INDUCTION OF LABOUR , 1975, The Lancet.
[68] S. Parikh,et al. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. , 1999, Biochemistry.
[69] W. Roper,et al. The new tuberculosis. , 1992, The New England journal of medicine.
[70] J. Mcgowan. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. , 2006, American journal of infection control.
[71] G. Domagk. Ein Beitrag zur Chemotherapie der bakteriellen Infektionen , 1935 .
[72] I. Taylor,et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. , 1999, Biochemistry.
[73] J. Sacchettini,et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. , 1998, Science.
[74] Peter J Tonge,et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. , 2006, ACS chemical biology.
[75] O. N. de Souza,et al. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. , 2006, Current pharmaceutical design.
[76] Chang Ki Kim,et al. In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea , 2007, Antimicrobial Agents and Chemotherapy.
[77] R. Angeletti,et al. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. , 2006, Biochemistry.
[78] S. Waksman,et al. Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.∗† , 1944, Clinical orthopaedics and related research.
[79] N. Kaplan,et al. In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis , 2007, Antimicrobial Agents and Chemotherapy.